Access the full text.
Sign up today, get DeepDyve free for 14 days.
K Kidd-Ljunggren, O Simonsen (1999)
Reappearance of hepatitis B 10 years after kidney transplantationN Engl J Med, 341
WQ Chen, BE Shan, RS Zheng, GZ Lin, JZ Chen, JG Chen, YT He (2012)
Analysis of incidence and mortality of leukemia in registration areas of China from 2003 to 2007Tumor, 32
Z Luo, L Li, B Ruan (2012)
Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year periodInt J Infect Dis, 16
ZH Zhang, L Li, XP Zhao, D Glebe, CM Bremer, ZM Zhang, YJ Tian, BJ Wang, Y Yang, W Gerlich, M Roggendorf, X Li, MJ Lu, DL Yang (2011)
Elimination of hepatitis B virus surface antigen and appearance of neutralizing antibodies in chronically infected patients without virus clearanceJ Viral Hepat, 18
P Schmeltzer, KE Sherman (2010)
Occult hepatitis B: clinical implications and treatment decisionsDig Dis Sci, 55
LT Hsiao, TJ Chiou, JP Gau, CF Yang, YB Yu, CY Liu, JH Liu, PM Chen, CH Tzeng, YJ Chan, MH Yang, YH Huang (2015)
Risk of reverse seroconversion of hepatitis B virus surface antigen in rituximab-treated non-hodgkin lymphoma patients: a large cohort retrospective studyMedicine (Baltimore), 94
W Shi, Z Zhang, C Ling, W Zheng, C Zhu, MJ Carr, DG Higgins (2013)
Hepatitis B virus subgenotyping: history, effects of recombination, misclassifications, and correctionsInfect Genet Evol, 16
ZH Zhang, L Zhang, MJ Lu, DL Yang, X Li (2009)
Establishment of reference sequences of hepatitis B virus genotype B and C in ChinaZhonghua Gan Zang Bing Za Zhi, 17
H Wang, M Fang, X Gu, Q Ji, D Li, SQ Cheng, F Shen, CF Gao (2014)
The intracellular HBV DNAs as novel and sensitive biomarkers for the clinical diagnosis of occult HBV infection in HBeAg negative hepatocellular carcinoma in ChinaPLoS One, 9
JP Power, M Chaar, J Temple, M Thomas, D Spillane, D Candotti, JP Allain (2010)
HBV reactivation after fludarabine chemotherapy identified on investigation of suspected transfusion-transmitted Hepatitis B virusJ Hepatol, 53
K Tamura, D Peterson, N Peterson, G Stecher, M Nei, S Kumar (2011)
MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methodsMol Biol Evol, 28
A Jemal, F Bray, MM Center, J Ferlay, E Ward, D Forman (2011)
Global cancer statisticsCA Cancer J Clin, 61
ZH Zhang, L Zhang, Y Dai, YF Zhang, J Li, X Li (2016)
Occult hepatitis B virus infection: Influence of S protein variantsVirol J, 13
(2012)
EASL clinical practice guidelines: management of chronic hepatitis B virus infectionJ Hepatol, 57
H Huang, X Li, J Zhu, S Ye, H Zhang, W Wang, X Wu, J Peng, B Xu, Y Lin, Y Cao, H Li, S Lin, Q Liu, T Lin (2014)
Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trialJAMA, 312
C Marinone, M Mestriner (2011)
HBV disease: HBsAg carrier and occult B infection reactivation in haematological settingDig Liver Dis, 43
Z Zhang, J Xia, B Sun, Y Dai, X Li, JF Schlaak, M Lu (2015)
In vitro and in vivo replication of a chemically synthesized consensus genome of hepatitis B virus genotype BJ Virol Methods, 213
JH Kao, PJ Chen, MY Lai, DS Chen (2004)
Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriersJ Med Virol, 72
KQ Hu (2002)
Occult hepatitis B virus infection and its clinical implicationsJ Viral Hepat, 9
JW Han, H Yang, HL Lee, SH Bae, JY Choi, JW Lee, HJ Kim, S Lee, SG Cho, CK Min, DW Kim, SK Yoon (2016)
Risk factors and outcomes of hepatitis B virus reactivation in hepatitis B surface antigen negative patients with hematological malignanciesHepatol Res, 46
M Paganelli, X Stephenne, EM Sokal (2012)
Chronic hepatitis B in children and adolescentsJ Hepatol, 57
AS Lok, BJ McMahon (2009)
Chronic hepatitis B: update 2009Hepatology, 50
CJ Chiang, YC Chen, CJ Chen, SL You, MS Lai (2010)
Cancer trends in TaiwanJpn J Clin Oncol, 40
JH Li, H Guo, XH Gao, HD Chen (2015)
Multiple skin ulcers from malignant syphilisLancet, 386
M Altfeld, JK Rockstroh, M Addo, B Kupfer, I Pult, H Will, U Spengler (1998)
Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawalJ Hepatol, 29
Z Zhang, L Zhang, Y Dai, L Jin, B Sun, Q Su, X Li (2015)
Occult hepatitis B virus infection among people with a family history of chronic hepatitis B virus infectionJ Med Virol, 87
YF Liaw, JH Kao, T Piratvisuth, HL Chan, RN Chien, CJ Liu, E Gane, S Locarnini, SG Lim, KH Han, D Amarapurkar, G Cooksley, W Jafri, R Mohamed, JL Hou, WL Chuang, LA Lesmana, JD Sollano, DJ Suh, M Omata (2012)
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 updateHepatol Int, 6
H Okamoto, F Tsuda, H Sakugawa, RI Sastrosoewignjo, M Imai, Y Miyakawa, M Mayumi (1988)
Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypesJ Gen Virol, 69
ZH Zhang, CC Wu, XW Chen, X Li, J Li, MJ Lu (2016)
Genetic variation of hepatitis B virus and its significance for pathogenesisWorld J Gastroenterol, 22
DK Wong, J Fung, CK Lee, WK Seto, J Leung, FY Huang, CK Lin, CL Lai, MF Yuen (2015)
Intrahepatic hepatitis B virus replication and liver histology in subjects with occult hepatitis B infectionClin Microbiol Infect, 22
G Raimondo, JP Allain, MR Brunetto, MA Buendia, DS Chen, M Colombo, A Craxì, F Donato, C Ferrari, GB Gaeta, WH Gerlich, M Levrero, S Locarnini, T Michalak, MU Mondelli, JM Pawlotsky, T Pollicino, D Prati, M Puoti, D Samuel, D Shouval, A Smedile, G Squadrito, C Trépo, E Villa, H Will, AR Zanetti, F Zoulim (2008)
Statements from the Taormina expert meeting on occult hepatitis B virus infectionJ Hepatol, 49
TH Westhoff, F Jochimsen, A Schmittel, M Stoffler-Meilicke, JH Schafer, W Zidek, WH Gerlich, E Thiel (2003)
Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapyBlood, 102
In this study, we assessed the prevalence of overt and occult hepatitis B virus (HBV) infection among leukemia patients. Among 256 leukemia patients and 377 fracture patients (control group), we found that the hepatitis B surface-antigen-positive rate was greater in leukemia patients than in the controls (odds ratio, 2.08; p = 0.01). Moreover, the prevalence of occult HBV infection was higher in leukemia patients than in the controls (10.5 % vs. 2.9 %; odds ratio, 3.92; p < 0.001). The HBV genotype distribution differed significantly between the leukemia and chronic hepatitis B or control groups (p < 0.001 and 0.01, respectively); specifically, genotype C was primarily observed in occult HBV infection patients with leukemia. The stop codon mutation rate or amino acid substitutions in the major hydrophilic region did not differ between the groups. Thus, the prevalence of occult hepatitis B is higher in leukemia patients, and the HBV genotype distribution differs between patients with leukemia and chronic hepatitis B virus infection.
Archives of Virology – Springer Journals
Published: Oct 14, 2016
Access the full text.
Sign up today, get DeepDyve free for 14 days.